

September 1, 2006

TO: ALL SOUTHWEST ONCOLOGY GROUP MEMBER, CCOP AND

AFFILIATE MEDICAL ONCOLOGISTS

FROM: SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE

RE: SWOG-9150, SWOG-9151, SWOG-9237, SWOG-9241, SWOG-9305,

SWOG-9339, SWOG-9510 and SWOG-9518

MEMORANDUM

The Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis (DCTD), NCI has withdrawn the DCTD-sponsored IND for Topotecan Hydrochloride, NSC-609699, <u>effective August 11, 2006</u>. Their records indicate that all DCTD-sponsored studies using this agent are closed and that all patients are off treatment with this agent.

FDA regulations require investigators to retain all research records, including patient charts, case report forms, x-rays and scans that document response, IRB approvals, signed informed consent documents and all drug accountability records for at least two years after the IND has been withdrawn. Please retain records until at least **August 11**, **2008**.

The Pharmaceutical Management Branch, CTEP has previously sent letters to all CTEP investigators and their designees to whom Topotecan Hydrochloride was supplied, advising them that CTEP was withdrawing the IND for this agent and requested the return of all CTEP-supplied Topotecan Hydrochloride, NSC 609699. If you have not already done so, please return all CTEP-supplied Topotecan Hydrochloride to the NCI Clinical Repository at 627 Lofstrand Lane, Rockville, MD 20850 ATTN: RETURNS. FDA regulations require all remaining supplies of this agent to be returned to the IND sponsor.

Please feel free to contact Dr. Dale Shoemaker for any regulatory questions and Mr. Charles Hall for any agent supply issues.

Dr. Dale Shoemaker Chief, Regulatory Affairs Branch CTEP, DCTD, NCI


E-mail: shoemakerd@mail.nih.gov

Phone: 301-496-7912 FAX: 301-402-1584 Mr. Charles Hall

Chief, Pharmaceutical Management Branch

CTEP, DCTD, NCI

E-mail: hallch@mail.nih.gov Phone: 301-496-5725 FAX: 301-402-0429



National Institutes of Health National Cancer Institute Bethesda, Maryland 20892

DATE:

August 14, 2006

FROM:

Acting Associate Chief, Regulatory Affairs Branch, CTEP, DCTD, NCI

SUBJECT:

Notice of Completed IND Withdrawal

TO:

See Below

The FDA has completed withdrawal of the IND for **Topotecan Hydrochloride**. The following information is provided regarding this IND:

Proper Name:

Topotecan Hydrochloride

Date Withdrawn:

August 11, 2006

IND Number:

34494

NSC Number:

609699

FDA Division:

CDER - Office of Oncology Drug Products

Division of Drug Oncology Products

Collaborating Drug Company:

GlaxoSmithKline

PIO Treatment Codes:

Topotecan

Reason for Withdrawal:

All trials are either complete or closed to accrual and treatment, except for protocol A3973 which is closed to accrual. If patients (maximum of two) require treatment with topotecan, they will be provided with commercial product. The DCTD, NCI, does not plan to activate further trials under this IND since topotecan is

commercially available.

Jan Casadei, Ph.D

Distribution:

Associate Director, DTP Chief, PMB and Staff

Chief, IDB and Staff PIO

Chief, CIB and Staff
Chief, TPB, DTP
Chief, RAB and Staff
Chief, PRB, DTP
Drug Monitor
DDG Coordinator

CTEP Support Coordinator, R & D Agreements